Successful Eradication of Hepatitis C Virus with Sofosbuvir based Antiviral treatment results in improvement in quality of life in cirrhotic patients

Abstract

Hepatitis C virus (HCV) infection has long been a serious global public health concern; it is not only the main cause of end-stage liver disease, but it is also a leading source of liver cancer, but it also increases the risk of mortality from a variety of extrahepatic illnesses. Objective: The study's main objective is to see if successfully eradicating the Hepatitis-C virus with sofosbuvir-based antiviral therapy improves cirrhotic patients' quality of life. Methods: This cross-sectional study was conducted in Faisalabad Medical University from June 2019 to June 2020. The data was collected from 70 patients. The data was collected through a non-probability consecutive sampling technique. Results: The data were collected from 70 patients of both genders. We compared patients' quality of life. With sofosbuvir and ribavirin, 56 patients (79%) reached Sustained Virologic Response 12 (SVR12), Sofosbuvir, daclatasvir, and ribavirin were administered to 13 patients (18%), while sofosbuvir and ledipasvir were administered to two individuals (3%).Conclusions: Infection with chronic HCV, which is made worse by cirrhosis, has a major negative influence on the patient's physical, mental, social, and functional well-being, leading to a considerable reduction in their overall quality of life.